Second study will assess sarilumab for Covid-19

The Phase II/III trial will evaluate the IL-6 inhibitor in the treatment of Covid-19 patients in Italy, Spain, Germany, France, Japan, Canada and Russia. This is the second trial of its kind, following anecdotal reports that tocilizumab showed efficacy in treating these patients.

Source:

Biospace Inc.